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Abstract Poor adherence to statins increases cardiovas-
cular disease risk. We systematically identified 32 con-
trolled studies that assessed patient-centered interventions
designed to improve statin adherence. The limited number
of studies and variation in study characteristics precluded
strict quality criteria or meta-analysis. Cognitive education
or behavioural counselling delivered face-to-face multiple
times consistently improved statin adherence compared
with control groups (7/8 and 3/3 studies, respectively).
None of four studies using medication reminders and/or
adherence feedback alone reported significantly improved
statin adherence. Single interventions that improved statin
adherence but were not conducted face-to-face included
cognitive education in the form of genetic test results (two
studies) and cognitive education via a website (one study).
Similar mean adherence measures were reported for 17
intervention arms and were thus compared in a sub-
analysis: 8 showed significantly improved statin adherence,
but effect sizesweremodest (?7 to?22 %points). In three of
these studies, statin adherence improveddespite already being
high in the control group (82–89 vs. 57–69 % in the other
studies). These three studies were the only studies in this sub-
analysis to include cognitive education delivered face-to-face
multiple times (plus other interventions). In summary, the
most consistently effective interventions for improving
adherence to statins have modest effects and are resource-
intensive. Research is needed to determine whether modern
communications, particularly mobile health platforms (re-
cently shown to improve medication adherence in other
chronic diseases), can replicate or even enhance the successful
elements of these interventions while using less time and
fewer resources.
Key Points
We narratively reviewed 32 systematically
identified, controlled studies that assessed
interventions designed to improve adherence to
statins.
Absolute increases in mean adherence to statins were
modest (?7 to ?22 %) for successful interventions
that used comparable adherence measures
(medication possession ratio, proportion of days
covered, or similar). Nevertheless, increased
adherence to statins generally also improved
cholesterol measures.
Cognitive education delivered face-to-face multiple
times was the most consistent feature of successful
interventions, although successful examples of other
intervention types (e.g. behavioural counselling),
were also found.
Most interventions that improve adherence to statins
are resource intensive, despite only having modest
effects. Mobile health platforms may be a more
efficient alternative, but have not been well explored
in relation to statin use.
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Hypercholesterolemia is one of the main modifiable risk
factors for cardiovascular disease (CVD) [1, 2]. There is
compelling evidence that statins are effective at reducing
lipid levels, the risk of CVD events and mortality [3, 4].
Concordantly, poor adherence to statins has been shown to
increase the risk of CVD morbidity and death [5–7].
Nonadherence to statins has been estimated to be about
50 % over 5 years, with the highest rates of discontinuation
observed during the first year of treatment [8–10]. Poor
adherence to medication is the result of complex interac-
tions between patient- physician- and healthcare-related
factors [11]. Patient-reported reasons for reduced adher-
ence to statins include insufficient knowledge of their
benefits (e.g. the belief that statins are unnecessary for
good health) uncertainty over whether treatment should be
continued because of a lack of follow-up by clinicians,
distrust of clinicians’ instructions, concerns about the
short- and long-term risks of taking statins, preferences for
alternative treatment such as herbal remedies, and the
inconvenience of taking lipid-lowering medications [e.g.
requirement for laboratory testing, complicated dosing
regimens—especially when patients are taking many dif-
ferent (not necessarily all CVD-related) medications]
[11–14]. Age (usually\50 years and C70 years), female
sex, lower income and use in primary prevention (relative
to secondary prevention) are also associated with nonad-
herence to statins [15]. Interventions to enhance adherence
to statins are warranted to improve health outcomes and
decrease medical costs. A number of high-quality reviews
have attempted to assess the impact of interventions on
adherence to medication in general [16–18], but none (to
our knowledge) have focused specifically on statins. The
main objectives of this narrative review were therefore to
undertake a systematic search for studies assessing the
impact of patient-centered interventions on adherence to
statins, systematically categorize interventions according to
their component parts, and then attempt to determine which
intervention components are the most effective.
2 Methods
2.1 Systematic Searches
Systematic searches were conducted in PubMed and
Embase for the period from January 2000 to January 2015
(see Fig. 1 PRISMA flow diagram). Medical Subject
Headings (MeSH) terms (PubMed) and ‘explosion’ terms
(Embase) were used when available. Intervention-related
search terms were difficult to define comprehensively, and
were not covered by standard MeSH terms. The search
string was therefore kept broad by including only terms
describing statins and adherence. Studies describing
patient-centered interventions were then identified manu-
ally at the post-search stage by screening titles/abstracts
and/or full papers. The systematic searches were performed
and screened by one author (SP) and then independently
reviewed by a second author (MM-B).
2.2 Study Inclusion Criteria
To be included, studies had to have a control arm and a
post-intervention study period of at least 3 months.
Prospective studies that were not randomized controlled
trials (RCTs) and retrospective studies were included pro-
vided that controls were matched to the intervention group
or, if unmatched controls were used, potential differences
in patient characteristics between the intervention and
control group (i.e. confounding) were adjusted for in the
statistical analysis. Studies assessing the impact of inter-
ventions on measures of persistence (defined as the length
of time between treatment initiation and the last dose [19])
that did not also include measures of implementation (de-
fined as the extent to which patients’ actual dosing corre-
sponds to the prescribed dosing regimen [19]) were not
considered to measure adherence to statins for the purposes
of this study and were therefore excluded. No other study
quality criteria were applied.
2.3 Classification of Interventions
There is no accepted system for classifying interventions
that target adherence to statins. We therefore adapted an
approach used in a recent systematic review of interven-
tions designed to enhance adherence to medication [16].
Components of each intervention were classified into 1 of 5
main categories: cognitive education, behavioural coun-
selling, medication reminder systems, adherence feedback
and treatment simplification (see Box 1 in Appendix for
detailed descriptions). Information on how interventions
were delivered (face-to-face, telephone, mail, etc.), and
whether they were delivered once or multiple times was
also collected systematically. Categorization of interven-
tions using this system was performed by two authors
(MM-B and SP) and was then independently reviewed (and
modified if necessary) by the remaining authors (MJK, MA
and SB). When more than one intervention component was
used in a study they were all captured as part of the
intervention classification. In this way, interventions of
varying complexity were represented. As with any review,
our analysis is limited by what was reported in each study.
We therefore cannot exclude the possibility that other
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intervention components were used in some studies but not
reported.
2.4 Analysis of Data on Adherence to Statins
Owing to considerable variation in study designs and the
small number of studies using just one type of intervention,
a meta-analysis of the data was not deemed appropriate.
We therefore performed a narrative synthesis of the
available data, consisting of two approaches. The first was
a broad attempt to identify potential commonalities/dif-
ferences in terms of interventions that significantly
improve adherence to statins. This analysis (represented in
Fig. 2) included all of the identified studies regardless of
the adherence measure used. The second, more stringent
analysis included only studies that used objective measures
of adherence to statins such as prescription refills, pill
counts or electronic monitoring systems and reported
Fig. 1 Flow diagram of searches and the study selection process
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absolute differences in mean statin adherence levels
[medication possession ratio (MPR), proportion of days
covered (PDC) or similar]. This analysis (represented in
Fig. 3) allowed the magnitude of the effects of different
interventions on adherence to statins to be compared, albeit
across fewer studies. The absolute mean difference in
Fig. 2 Combinations of components used in intervention groups
(n = 34) to try to improve adherence to statins. Each column
represents one intervention group. Intervention groups are ranked by
the number of components involved. Components in each interven-
tion group are illustrated by blue boxes (those in yellow boxes were
applied to both the intervention group and the control group). Pink
boxes highlight components that were not applied to all patients in the
intervention group. Columns with interventions associated with a
significant improvement in at least one measure of adherence are
highlighted in green. Letters in boxes denote whether the component
was used a single time (S) or multiple times (M). Symbols indicate
who delivered the intervention: *physician; pharmacist; and nurse.
Roman numerals indicate the number of ‘other’ intervention compo-
nents used. The full text of the descriptions of the interventions used
in each study in relation to how they were categorized is provided in
Supplementary Table 1 (online)
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adherence to statins between an intervention and a control
group was considered to be more transparent and clinically
meaningful than differences in the proportion of adherent
patients, which tend to be based on fairly arbitrary defini-
tions of what constitutes adherence (e.g. MPR C 0.80), and
can underestimate or overestimate the impact of an inter-
vention depending on how close patients already are to
meeting the definition of adherence being used. For
example, if most patients in a population have a mean MPR
of 0.75 (i.e. currently taking 75 % of their doses), an
intervention causing an absolute increase in mean adher-
ence to medication of 6 % might shift a high proportion of
patients from being defined as non-adherent to being
defined as adherent, despite the questionable clinical sig-
nificance of such a small effect.
3 Results
3.1 Searches
Of 3613 combined search ‘hits’, 32 studies were identified
that fulfilled the inclusion criteria [20–51]. The main rea-
sons for exclusion were: irrelevant study topic, intervention
directed towards healthcare professionals (rather than
being patient-centered), intervention not sufficiently
described and insufficient data on adherence to statins.
3.2 Study Characteristics
Most (20/32) of the included studies were conducted in
North America [21–24, 26–30, 32, 36, 37, 43, 45–51], with
9 conducted in Europe [20, 31, 34, 35, 38, 39, 41, 42, 44]
and 3 in Asia [25, 33, 40]. The median sample size for the
intervention group was 202 (range: 15–29,042) and the
median study duration was 12.0 months (range: 3 months–
2 years). Many studies did not specify the reason for statin
use in the included patients [23, 24, 26, 27, 29–31,
38, 41–43, 47, 49, 50]. Of those that did, half indicated that
statins were prescribed for secondary CVD prevention
[20–22, 25, 33, 44–46, 48]. Other indications included
primary hypercholesterolemia [35], diabetes [28, 32] and
elevated CVD risk [36, 37, 39, 51]. Five studies selected
patients based on poor adherence to statin therapy
[24, 26, 31, 36, 38]. Two studies [31, 32] contained 2
intervention arms; hence, data from 34 intervention arms
were included in the overall analysis. Study designs,
patient characteristics, intervention types (based on the
categorization used in Fig. 2) and the methods and raw data
for all statin adherence (implementation and persistence)
and cholesterol measures used in each study are summa-
rized in Table 1. The full published descriptions of the
interventions used in each study and how they were cate-
gorized for inclusion in this review are provided in Sup-
plementary Table 1 (online).
3.3 Interventions and Statin Adherence
(Implementation)
The first parts of this section of the narrative synthesis (Sects.
3.3.1–3.3.4) draw on data in Fig. 2, which presents all
identified studies in order (from left to right) of the increasing
number of intervention components they contained. In sev-
eral of these studies the outcome measure for adherence to
Fig. 3 Studies reporting the mean proportion of days covered,
medication possession ratio or similar parameter by intervention
type. 1 Cognitive education, 2 behavioural counselling, 3 treatment
simplification, 4 medication reminders, 5 adherence feedback, A face-
to-face, B telephone (person), C hard copy materials, D telephone
(automated), E other delivery components (Roman numerals indicate
number of other delivery components), S single time, M multiple
times. *Statistically significant difference between control and
intervention groups (p\ 0.05)
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statins was not defined [25, 33, 39], was described only as
self-reported [24, 37], or used patient-reported question-
naires to estimate adherence to statins [29, 34], increasing the
risk of bias in their reported results. Section 3.3.5 draws on
data in Fig. 3, which presents studies in the same order as
Fig. 2 but is limited to those using more reliable outcome
measures of adherence to statins, and includes a quantitative
component (absolute differences in mean statin adherence
levels based on MPR, PDC or similar between intervention
and control). Nevertheless, trends in either analysis may still
be biased by substantial variation in other study character-
istics (Table 1), or be due to chance alone owing to the small
number of available studies. While we have done our best to
only report robust trends that (in the collective opinion of the
authors) are unlikely to be artefactual, the reader should
factor the above limitations into their interpretation of the
results.
3.3.1 Cognitive Education Interventions
Cognitive education was the most frequently included
intervention (Fig. 2). Only 3 studies (all RCTs) of 13 that
used cognitive education as the only type of intervention
did not report significantly improved adherence to statins
compared with controls (Fig. 2; Table 1) [22, 41, 51]. Most
(8/10) of the studies that did report significantly improved
adherence to statins with cognitive education only were
RCTs or used a similarly unbiased prospective study design
(randomization at hospital rather than patient level, inter-
vention assigned based on appointment times, or patients
used as own controls) (Table 1) [20, 21, 25, 33, 34,
36, 37, 40]. The other two studies were prospective but not
randomized: one used a matched control group, while the
other used an un-matched control group but adjusted the
statistical analysis for confounders (Table 1) [23, 24].
There were seven RCTs (or similar) and one prospective
study that included multiple, face-to-face, cognitive edu-
cation sessions in their interventions (Table 1)
[33–35, 38, 40–42, 48]. All of these, except for Eussen et al
[41], reported a statistically significant improvement in
adherence to statins (Fig. 2). Conversely, Eussen et al was
the only one of 14 studies that did not report a statistically
significant improvement in adherence to statins that
included multiple, face-to-face, cognitive education ses-
sions (Fig. 2). Importantly, Eussen et al reported very high
mean adherence to statins (MPR of 99 %) in the control
group (Fig. 3) [41], which would make it impossible to
resolve an effect on adherence to statins even if one existed
for this intervention.
There were nine studies that included a single, face-to-
face, cognitive education session in their intervention, of
which eight were RCTs or similar and one was a
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[20, 21, 31, 36, 37, 43, 45, 46, 51]. Of the five studies that
reported a statistically significant improvement in adher-
ence to statins, all except Yilmaz et al [20] also included
cognitive-education delivered multiple times via other
methods (telephone, hard-copy materials or both), com-
pared with none of the four studies that did not show
improved adherence to statins (Fig. 2).
There were three studies that achieved a significant
improvement in adherence to statins despite including only
a single cognitive education session that was not delivered
face-to-face (Fig. 2). Two of these studies (both prospec-
tive but not randomized) were unique in providing patients
with test results for genetic polymorphisms as the sole
intervention: one genetic variant was associated with an
increased risk of myopathy with statin use and premature
discontinuation (SLCO1B1*5 gene variant; genotyping
information provided via a website) [24] and the other
variant had the potential to modulate reductions in coro-
nary heart disease risk in statin users (KIF6 gene variant;
genotyping information provided in hard copy form along
with genotype-guided treatment recommendations) [23]. In
one of these studies, adherence to statins was defined as
self-reported, while the other reported adherence to statins
as the mean PDC [23, 24]. The third study, by Peng and
colleagues, did not define the outcome measure used to
assess adherence to statins and employed a clustered (by
hospital) randomized study design in which cognitive
education materials were provided to the intervention
group via a password-protected website [25].
3.3.2 Behavioural Counselling
All three studies that used multiple, face-to-face beha-
vioural counselling sessions significantly improved adher-
ence to statins (mean MPR or PDC) relative to the control
group (Fig. 2) [26, 27, 35]. Behavioural counselling con-
sisted of motivational interviews in two of these studies
(one retrospective and one where patients were their own
controls) and was used alone [26, 27]. In the third study, an
RCT, behavioural counselling consisted of patients being
asked to adopt a new routine to remind them to take their
medication, but was combined with multiple, face-to-face
cognitive education sessions [35]. Further patterns regard-
ing the impact of behavioural counselling on adherence to
statins were difficult to discern from the data in Fig. 2.
3.3.3 Treatment Simplification
Two studies included treatment simplification in their
intervention, both of which reported a significant increase
in adherence to statins (Fig. 2). One of these studies was an
RCT that combined treatment simplification with multiple
cognitive education sessions (face-to-face and via
automated calls), a single behavioural counselling inter-
vention (pillbox) and medication reminders [48]. The other
study, by Holdford et al, was a non-randomized prospective
study that we classified as using treatment simplification
plus an optional behavioural counselling component (pill
box) [50]. The appointment based medication synchro-
nization (ABMS) intervention program described in the
Holdford et al study also included the optional use of
‘medication therapy management’. We could not confi-
dently define this component for inclusion in our classifi-
cation system, but it should be noted that descriptions of
ABMS reported elsewhere indicate it may involve multiple
face-to-face behavioural counselling and/or cognitive
education sessions [52]. Thus, ABMS may be a more
complex intervention than we are able to report here based
on our classification of the Holdford et al study.
3.3.4 Medication Reminders and Adherence Feedback
There were eight interventions across five RCTs and one
retrospective study that were based on medication remin-
ders and/or adherence feedback (Table 1)
[30–32, 39, 42, 48]. All except one of these studies used the
MPR, PDC or similar for their outcome measure of
adherence to statins. None of the study arms that used only
medication reminders and/or adherence feedback reported
a significant impact on adherence to statins (Fig. 2). The
only two studies using these intervention components that
reported significantly increased mean adherence to statins
combined them with multiple, face-to-face cognitive edu-
cation sessions (Fig. 2).
3.3.5 Comparative Effect Sizes for Different Interventions
There were 17 intervention arms across 10 RCTs (or
similar), 4 prospective studies and 2 retrospective studies
that reported data on adherence to statins using similar,
clinically meaningful measures (e.g. mean MPC or PDC)
(Table 1) [22, 23, 26–28, 30, 32, 35, 41–45, 48–50]. Sig-
nificantly increased mean adherence to statins relative to
the control group was achieved in three of the seven studies
that used only one intervention type: two used multiple,
face-to-face motivational interviews [?5 and ?7 % points
(both behavioural counselling)] [26, 27] and one provided
genotyping information for the KIF6 gene variant [?9 %
points (cognitive education)] [23] (Fig. 3). These effect
sizes are within the range observed in the five studies that
combined more than one intervention type and achieved
significantly improved adherence to statins (?7 to ?22 %
points) (Fig. 3) [35, 42, 43, 48, 50]. It is worth noting that
the significant improvement in adherence to statins in three
of the latter studies occurred despite having much higher
mean adherence to statins in the control groups (range:
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82–89 %) [35, 42, 48] compared with the three studies that
significantly improved adherence to statins using a single
intervention type (range: 57–68 %) [23, 26, 27] (Fig. 3).
These were also the only studies (other than Eussen et al
[41]) in this sub-analysis to incorporate multiple, face-to-
face cognitive education sessions into their intervention.
3.4 Interventions and Statin Adherence
(Persistence)
Adherence to statins was measured in terms of persistence
as well as implementation in nine RCTs, five prospective
studies and one retrospective study (Table 1)
[20, 22–24, 27, 31, 35, 38, 41–44, 47, 49, 50]. Of 10 studies
that measured both of these parameters and reported sig-
nificantly improved statin implementation compared with
controls only Kardas et al did not also report significantly
improved persistence (Table 1) [35]. Conversely, of five
studies that reported no significant effect of the interven-
tion on statin implementation, only Eussen et al reported
any significant effect on persistence [41].
3.5 Impact of Improved adherence to Statins
on Cholesterol Measures
The impact of interventions on cholesterol measures (mean
LDL–C, LDL–C change from baseline, proportion reach-
ing target LDL–C levels) was reported in addition to their
impact on adherence to statins in nine RCTs (or similar)
and two prospective studies (Table 1) [20, 21, 24, 32, 34,
36, 39, 40, 45, 48, 51]. Of the seven studies reporting
improved adherence to statins with their intervention, five
also reported a significant improvement in at least one
cholesterol measure (Table 1). All four studies reporting no
significant improvement in adherence to statins also
reported no significant improvement in any cholesterol
measure.
4 Discussion
There is growing interest in establishing which interven-
tions can improve adherence to statins, as evidenced by the
fact that most [22/32 (69 %)] of the studies we identified
were published in 2010 or later (the search string was
designed to capture any articles published since 2000). A
number of high-quality reviews have attempted to assess
the impact of interventions on adherence to medication
[16–18]. However, to our knowledge, we are the first to
undertake a systematic search for and analysis of studies
addressing this problem in relation to statin use.
We categorized interventions according to their com-
ponent parts, who delivered them and how they were
delivered, in an attempt to identify those that genuinely
improve adherence to statins. The main limitation of this
approach (others are discussed below) is that most inter-
ventions assessed in the literature include more than one
type of component, making it difficult to know what con-
tribution individual components are adding to observed
improvements in adherence to statins. For this reason, and
because of considerable variation in study designs, meta-
analysis was not deemed appropriate. Despite these limi-
tations, some interesting trends were observed in our nar-
rative synthesis of the data, from which we believe some
cautious inferences can be drawn.
Our findings suggest that face-to-face cognitive educa-
tion interventions are effective at improving patient
adherence, particularly if delivered more than once.
Notable exceptions to this were two studies that provided
patients with the results of pharmacogenetic tests that were
potentially relevant to the efficacy or adverse effects of
their statin treatment [23, 24]. These results were delivered
only once by mail or via a website and yet significantly
improved adherence to statins. It is possible that the benefit
of this form of educational material lies in its highly per-
sonalized nature, directly linking the treatment to the
individual and thus providing motivation for patients to
modify medication adherence behaviours.
Although only a few studies were available that used
medication reminders or adherence feedback, the data were
consistent in showing that these intervention components
did not have a significant impact on adherence to statins.
The only study that used these interventions and signifi-
cantly improved adherence to statins also used a face-to-
face cognitive education component delivered multiple
times, which was the most consistently successful inter-
vention type identified in this review and could therefore be
responsible for the observed improvement in adherence to
statins in this study [42].
It was also noted that studies using multiple intervention
types improved adherence to statins despite mean adher-
ence levels that were generally higher in their control
groups than in the control groups of studies that only used
one type of intervention. It may be that combining different
intervention types is a more effective strategy for
improving adherence to statins in populations that already
have a relatively high level of statin adherence, although
the use of multiple, face-to-face, cognitive education ses-
sions was also a common feature of these studies and could
thus have constituted the main ‘active’ component.
Measuring medication adherence accurately is extre-
mely difficult with currently available methods. Several
approaches were used in the studies we identified, most of
which were indirect and thus questionable in terms of their
reliability. The most common method involved monitoring
prescription refills, but this merely measures medication
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possession, not consumption. Indeed, many patients may
feel obliged to refill their prescriptions according to their
doctor’s instructions, regardless of whether they take the
medication. More direct methods of assessing adherence to
medication, such as medication event monitoring systems
(MEMS), which electronically monitor when medication
bottles are opened, and biomarker detection systems, which
directly assess medication consumption (e.g. by measuring
drug metabolites in urine or plasma), may be better options.
However, MEMS is very costly (used in only one of our
identified studies [42]), and assessment of biomarkers of
adherence to medication may impose a substantial burden
on the patient. It is possible, however, that these issues may
be overcome in the future. For example, refinement of
MEMS technology and its incorporation into the ‘Internet
of things’ may enhance affordability, while novel sensor
technology and wearables have the potential to increase the
practicality of biomarker detection.
Another significant challenge when quantifying the
impact of different interventions on adherence tomedication
is the lack of standardization in terms of how it is compared.
In our first analysis we looked for broad, over-reaching
patterns in the data that held across different studies in spite
of variation in how adherence was measured, or other dif-
ferences in study characteristics such as study design and
patient characteristics. In our second analysis, we compared
only studies that assessed the absolute change in adherence
to statins (based on MPR, PDC or similar), rather than the
proportion of patients shifted towards ‘adherent behaviour’
by interventions. We made this choice because measuring
adherent behaviour means that arbitrary thresholds must be
defined and this may give an inaccurate impression of the
impact of an intervention. Indeed, several studies included in
this review reported both absolute change in adherence to
statins and the changes in the proportion of patients defined
as being adherent to statins, with the latter giving values
approximately twice that of the absolute change. The med-
ical relevance of any medication adherence measure can of
course be debated, but to help to quantify and compare dif-
ferent interventions, we recommend absolute difference in
adherence to medication as the most transparent and easily
interpretable measure.
The exact content of the interventions used in several of
the included studies could not be easily quantified or cat-
egorized, often because it is not practical to publish full
details of the materials used to deliver interventions,
especially for cognitive education and behavioural coun-
selling approaches (e.g. interview guides, educational
pamphlets, videos). Thus, differences between studies that
impact on the relative success of their interventions have
almost certainly been missed by our broad (though neces-
sarily practical) method of categorization. Furthermore,
distinguishing between cognitive education and
behavioural counselling approaches can often be concep-
tually difficult and is prone to subjective interpretation.
Nevertheless, any such misclassification would not be
likely to be systematically biased in any particular direction
and therefore would be unlikely to influence the broad and
tentative conclusions of this review.
To our knowledge, none of the interventions identified in
this review have been broadly implemented in general
healthcare practices. This is most likely to be due to the poor
cost effectiveness associated with the most effective inter-
ventions, namely cognitive education (and potentially
behavioural counselling) delivered viamultiple, face-to-face
sessions. These approaches are extremely resource intensive
(for both patients and providers), requiring substantial time,
planning and travel, and appear to have only modest effects.
Indeed, the cost of the intervention in the study by Ho and
colleagues (the only study providing such data) was esti-
mated at US$360 per patient-year, but yielded a mean
increase in the proportion of days covered by statins of only
11 percentage points [48]. The challenge is therefore to find
alternatives that can offer similar or enhanced benefits
compared with face-to-face consultations but that can be
maintained on a long-term basis across the population at an
affordable cost. One such alternative could be the use of
mobile health (mHealth), which uses smart phone or tablet
applications and thus has the potential to reachmany patients
at a relatively low cost. Compared with other approaches,
mHealth has the potential for greater personalization, which
appears to be a key factor in effective interventions. A recent
review by Hamine et al found that adherence to medication
was improved in 56 % of RCTs that used mHealth approa-
ches in patients with chronic diseases [53].
5 Conclusion
In this narrative synthesis of 32 systematically identified
studies we found consistent evidence that cognitive edu-
cation (and possibly also behavioural counselling) delivered
face-to-face multiple times improves adherence to statins.
Although absolute increases in mean adherence to statins
were fairly modest for these interventions (?7 to ?22 %),
they did tend to be associated with improvements in
cholesterol measures. However, these types of interventions
are extremely resource intensive and thus are often too
costly to apply to the general population. Modern commu-
nication and sensor technology in the form of mHealth have
recently been used to improve adherence to other chronic
disease medications. The lack of studies using these appli-
cations to improve adherence to statins suggests that this
promising approach has not yet been properly investigated
in this therapy area. Given the successful application of
mHealth elsewhere, there is reason to be optimistic that the
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challenge of improving general adherence to statins can be
met. Research in this area should be a priority.
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